CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.5664
1.95%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.0172
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Akebia Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.5364
Open* 1.5764
1-Year Change* 87.71%
Day's Range* 1.5364 - 1.6164
52 wk Range 0.24-1.84
Average Volume (10 days) 1.61M
Average Volume (3 months) 36.40M
Market Cap 170.86M
P/E Ratio -100.00K
Shares Outstanding 188.31M
Revenue 200.41M
EPS -0.54
Dividend (Yield %) N/A
Beta 0.81
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 29, 2024 1.5664 0.0000 0.00% 1.5664 1.6264 1.5364
Feb 28, 2024 1.5364 -0.1100 -6.68% 1.6464 1.6464 1.5364
Feb 27, 2024 1.6264 0.1100 7.25% 1.5164 1.6664 1.4764
Feb 26, 2024 1.4964 0.1400 10.32% 1.3564 1.5264 1.3564
Feb 23, 2024 1.3464 -0.0400 -2.89% 1.3864 1.3864 1.3164
Feb 22, 2024 1.3864 -0.0300 -2.12% 1.4164 1.4564 1.3764
Feb 21, 2024 1.4064 -0.0400 -2.77% 1.4464 1.4664 1.4064
Feb 20, 2024 1.4264 -0.0300 -2.06% 1.4564 1.4964 1.4164
Feb 16, 2024 1.4364 -0.0100 -0.69% 1.4464 1.4664 1.4264
Feb 15, 2024 1.4564 -0.0700 -4.59% 1.5264 1.5264 1.3964
Feb 14, 2024 1.5164 -0.0300 -1.94% 1.5464 1.5664 1.5164
Feb 13, 2024 1.5064 -0.1000 -6.23% 1.6064 1.6064 1.4964
Feb 12, 2024 1.6164 -0.0100 -0.61% 1.6264 1.6564 1.6064
Feb 9, 2024 1.6164 -0.0200 -1.22% 1.6364 1.6564 1.6164
Feb 8, 2024 1.6264 -0.0100 -0.61% 1.6364 1.6764 1.6164
Feb 7, 2024 1.6464 -0.0100 -0.60% 1.6564 1.6864 1.6164
Feb 6, 2024 1.6564 0.0300 1.84% 1.6264 1.7164 1.6264
Feb 5, 2024 1.6364 0.0200 1.24% 1.6164 1.6764 1.5864
Feb 2, 2024 1.6364 -0.0400 -2.39% 1.6764 1.6764 1.6164
Feb 1, 2024 1.6964 0.0100 0.59% 1.6864 1.7264 1.6364

Akebia Ther Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Akebia Therapeutics Inc Earnings Release
Q4 2023 Akebia Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Akebia Therapeutics Inc Earnings Release
Q1 2024 Akebia Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, June 5, 2024

Time (UTC)

14:00

Country

US

Event

Akebia Therapeutics Inc Annual Shareholders Meeting
Akebia Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 292.484 211.65 294.644 335.001 207.742
Revenue 292.484 211.65 294.644 335.001 207.742
Total Operating Expense 374.169 476.152 672.47 621.289 385.903
Selling/General/Admin. Expenses, Total 138.601 174.14 154.099 149.455 87.061
Research & Development 129.986 147.852 218.485 322.969 291.007
Operating Income -81.685 -264.502 -377.826 -286.288 -178.161
Interest Income (Expense), Net Non-Operating -15.687 -19.936 -8.871 0.792 6.154
Other, Net 3.146 2.414 1.856 -0.794 0.081
Net Income Before Taxes -94.226 -282.024 -384.841 -286.29 -171.926
Net Income After Taxes -94.226 -282.024 -384.841 -279.659 -143.588
Net Income Before Extra. Items -94.226 -282.024 -384.841 -279.659 -143.588
Net Income -94.226 -282.024 -384.841 -279.659 -143.588
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -94.226 -282.024 -384.841 -279.659 -143.588
Income Available to Common Incl. Extra. Items -94.226 -282.024 -384.841 -279.659 -143.588
Diluted Net Income -94.226 -282.024 -384.841 -279.659 -143.588
Diluted Weighted Average Shares 182.783 165.95 138.463 118.396 58.0382
Diluted EPS Excluding Extraordinary Items -0.51551 -1.69945 -2.77937 -2.36207 -2.47402
Diluted Normalized EPS -0.25816 -1.60907 -1.80421 -2.36207 -2.47402
Cost of Revenue, Total 22.501 103.118 132.244 112.464 6.318
Gross Profit 269.983 108.532 162.4 222.537 201.424
Depreciation / Amortization 36.042 36.042 32.617 36.401 1.517
Total Extraordinary Items
Unusual Expense (Income) 47.039 15 135.025
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 56.376 40.005 55.062 48.964 126.365
Revenue 56.376 40.005 55.062 48.964 126.365
Cost of Revenue, Total 9.222 11.747 -10.481 29.679 10.481
Gross Profit 47.154 28.258 65.543 19.285 115.884
Total Operating Expense 65.896 65.603 63.076 98.044 92.29
Selling/General/Admin. Expenses, Total 27.036 25.054 30.549 30.918 32.24
Research & Development 20.197 19.686 32.776 27.35 26.027
Depreciation / Amortization 9.011 9.01 9.01 9.011 9.011
Operating Income -9.52 -25.598 -8.014 -49.08 34.075
Interest Income (Expense), Net Non-Operating -1.642 -1.562 -1.636 -3.952 -5.037
Other, Net -0.01 0.282 0.434 1.167 0.411
Net Income Before Taxes -11.172 -26.878 -9.216 -51.865 29.449
Net Income After Taxes -11.172 -26.878 -9.216 -51.865 29.449
Net Income Before Extra. Items -11.172 -26.878 -9.216 -51.865 29.449
Net Income -11.172 -26.878 -9.216 -51.865 29.449
Income Available to Common Excl. Extra. Items -11.172 -26.878 -9.216 -51.865 29.449
Income Available to Common Incl. Extra. Items -11.172 -26.878 -9.216 -51.865 29.449
Diluted Net Income -11.172 -26.878 -9.216 -51.865 29.449
Diluted Weighted Average Shares 186.817 186.308 184.004 183.882 190.375
Diluted EPS Excluding Extraordinary Items -0.0598 -0.14427 -0.05009 -0.28206 0.15469
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.0575 -0.1437 -0.04344 -0.27615 0.23102
Unusual Expense (Income) 0.43 0.106 1.222 1.086 14.531
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 185.182 271.149 371.437 309.533 468.275
Cash and Short Term Investments 90.466 149.8 268.69 147.694 321.64
Cash & Equivalents 90.466 149.8 228.698 147.449 104.644
Short Term Investments 39.992 0.245 216.996
Total Receivables, Net 40.284 51.581 26.853 38.864 16.666
Accounts Receivable - Trade, Net 40.284 51.581 26.853 38.864 16.666
Prepaid Expenses 32.864 33.14 14.877 6.626 15.724
Total Assets 356.054 529.347 644.139 771.201 996.54
Property/Plant/Equipment, Total - Net 34.372 40.606 35.498 39.418 8.023
Property/Plant/Equipment, Total - Gross 48.271 41.237 43.082 9.981
Accumulated Depreciation, Total -7.665 -5.739 -3.664 -1.958
Other Long Term Assets, Total 5.372 50.421 37.981 75.985 137.036
Total Current Liabilities 129.536 261.051 187.146 208.118 265.693
Accounts Payable 18.021 33.588 41.308 39.217 42.796
Accrued Expenses 75.777 109.014 130.624 129.071 150.917
Notes Payable/Short Term Debt 0 0 0 0 15
Other Current Liabilities, Total 3.738 20.906 15.214 39.83 56.98
Total Liabilities 350.824 455.339 396.521 376.444 360.612
Total Long Term Debt 34.078 0 96.378 75.805 0
Other Liabilities, Total 187.21 194.288 112.997 92.521 88.288
Total Equity 5.23 74.008 247.618 394.757 635.928
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.002 0.001 0.001 0.001 0.001
Additional Paid-In Capital 1562.25 1536.8 1425.11 1188.81 1150.58
Retained Earnings (Accumulated Deficit) -1557.03 -1462.8 -1177.51 -794.054 -514.395
Treasury Stock - Common
Other Equity, Total 0.006 0.006 0.013 0 -0.261
Total Liabilities & Shareholders’ Equity 356.054 529.347 644.139 771.201 996.54
Total Common Shares Outstanding 184.136 177.001 148.074 121.675 116.888
Total Inventory 21.568 36.628 61.017 116.349 114.245
Goodwill, Net 59.044 59.044 55.053 55.053 55.053
Intangibles, Net 72.084 108.127 144.17 291.212 328.153
Deferred Income Tax 0 6.631
Current Port. of LT Debt/Capital Leases 32 97.543 0
Long Term Debt 34.078 0 96.378 75.805
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 109.602 118.447 120.719 185.182 237.512
Cash and Short Term Investments 46.529 53.572 56.953 90.466 144.761
Cash & Equivalents 46.529 53.572 56.953 90.466 144.761
Short Term Investments
Total Receivables, Net 22.592 19.572 17.781 40.284 23.094
Accounts Receivable - Trade, Net 22.592 19.572 17.781 40.284 23.094
Total Inventory 18.442 20.905 20.604 21.568 40.039
Prepaid Expenses 22.039 24.398 25.381 32.864 29.618
Total Assets 234.998 253.712 276.858 356.054 435.894
Property/Plant/Equipment, Total - Net 17.437 18.81 32.774 34.372 35.959
Goodwill, Net 59.044 59.044 55.053 59.044 55.053
Intangibles, Net 45.053 54.063 63.074 72.084 81.095
Other Long Term Assets, Total 3.862 3.348 5.238 5.372 26.275
Total Current Liabilities 79.702 92.184 82.944 129.536 187.965
Accounts Payable 9.038 11.776 12.577 18.021 19.708
Accrued Expenses 62.664 56.408 46.367 75.777 87.364
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0 0 3.738 14.946
Total Liabilities 274.42 280.519 291.21 350.824 422.041
Total Long Term Debt 34.613 18.486 26.296 34.078 0
Long Term Debt 34.613 18.486 26.296 34.078
Other Liabilities, Total 160.105 169.849 181.97 187.21 234.076
Total Equity -39.422 -26.807 -14.352 5.23 13.853
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 1570.13 1568.26 1564.77 1562.25 1559.21
Retained Earnings (Accumulated Deficit) -1609.56 -1595.07 -1579.13 -1557.03 -1545.36
Other Equity, Total 0.006 0.006 0.006 0.006 0.006
Total Liabilities & Shareholders’ Equity 234.998 253.712 276.858 356.054 435.894
Total Common Shares Outstanding 188.314 188.129 185.836 184.136 183.952
Current Port. of LT Debt/Capital Leases 8 24 24 32 65.947
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -92.562 -282.84 -383.457 -279.659 -143.588
Cash From Operating Activities -73.154 -252.965 -110.388 -257.441 -97.494
Cash From Operating Activities 1.654 1.927 2.075 2.245 0.899
Non-Cash Items -7.304 100.323 253.149 89.272 35.993
Changes in Working Capital -10.985 -108.418 -13.67 -105.7 7.68
Cash From Investing Activities -0.114 39.941 -40.004 211.176 36.594
Capital Expenditures -0.114 -0.059 -0.317 -6.655 -1.606
Other Investing Cash Flow Items, Total 0 40 -39.687 217.831 38.2
Cash From Financing Activities 14.598 133.731 231.72 88.97 96.562
Issuance (Retirement) of Stock, Net 7.598 88.948 211.745 26.302 96.581
Issuance (Retirement) of Debt, Net -33 0 19.975 62.668 -0.019
Net Change in Cash -58.67 -79.293 81.328 42.705 35.662
Amortization 36.043 36.043 31.515 36.401 1.522
Cash Interest Paid 6.755 9.632
Financing Cash Flow Items 40 44.783
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -26.217 -92.562 -85.01 -33.145 -62.421
Cash From Operating Activities -17.538 -73.154 -18.475 -52.28 -21.62
Cash From Operating Activities 0.398 1.654 1.246 0.833 0.417
Amortization 9.011 36.043 27.032 18.021 9.011
Non-Cash Items 3.105 -7.304 45.325 20.782 10.102
Changes in Working Capital -3.835 -10.985 -7.068 -58.771 21.271
Cash From Investing Activities 0 -0.114 -0.114 -0.114 -0.114
Capital Expenditures 0 -0.114 -0.114 -0.114 -0.114
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities -15.966 14.598 14.599 47.536 47.545
Financing Cash Flow Items 0 40 40 40 40
Issuance (Retirement) of Stock, Net 0.034 7.598 7.599 7.536 7.545
Net Change in Cash -33.504 -58.67 -3.99 -4.858 25.811
Cash Interest Paid
Issuance (Retirement) of Debt, Net -16 -33 -33
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Satter Management Co., L.P. Private Equity 8.6054 16205119 0 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1479 7811061 -4699843 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 3.9617 7460353 -22700 2023-06-30 MED
Renaissance Technologies LLC Hedge Fund 1.7687 3330727 992227 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.4452 2721451 70299 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.0652 2005958 1095000 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9415 1772977 90479 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.7688 1447834 147308 2023-06-30 MED
Butler (John P) Individual Investor 0.7015 1321052 -105042 2023-03-31 LOW
Federated MDTA LLC Investment Advisor/Hedge Fund 0.5125 965193 -54839 2023-06-30 HIGH
Victory Capital Management Inc. Investment Advisor/Hedge Fund 0.3515 661898 404154 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3325 626050 -66786 2023-06-30 LOW
Connor, Clark & Lunn Investment Management Ltd. Investment Advisor/Hedge Fund 0.3265 614878 311901 2023-06-30 MED
Fidelity Management & Research Company LLC Investment Advisor 0.3258 613590 0 2023-06-30 LOW
Dahan (Michel) Individual Investor 0.2815 530036 304522 2023-05-25 HIGH
Hadas Nicole R Individual Investor 0.2498 470343 236814 2023-05-25 HIGH
Qube Research & Technologies Ltd Hedge Fund 0.2317 436269 436269 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 0.2187 411847 55461 2023-06-30 HIGH
Snow (Ellen) Individual Investor 0.1965 370000 370000 2023-07-31 HIGH
XTX Markets LLC Venture Capital 0.1802 339367 339367 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Akebia Ther Company profile

Akebia Ther
Industry: Bio Therapeutic Drugs

245 First Street
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.60 Price
-0.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,052.19 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0112%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

62,640.65 Price
+1.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,056.00 Price
+0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading